Becker K, Stegenga S, Conway S
Department of Biological Sciences, Northern Illinois University, De Kalb 60115, USA.
Neuroendocrinology. 1995 May;61(5):573-83. doi: 10.1159/000126882.
In vivo and in vitro (static incubation and perifusion) procedures were used to examine the role of insulin-like growth factors (IGFs) in growth hormone (GH) feedback. An alpha 2-adrenergic agonist, clonidine (CLON; 2 x 10(-8) M in vitro or 30 micrograms/ml/kg body weight i.v. in vivo), which mimics the hypothalamic mechanism triggering GH release, was injected to induce a GH surge. Feedback was initiated by human GH (hGH; 2 x 10(-6) M) in vitro or ovine GH (oGH) (20 micrograms/2 microliters intraventricularly) in vivo. GH-releasing factor (GRF; 1 x 10(-8) M) was added at the end of in vitro experiments to test pituitary responsiveness. The involvement of somatostatin (SRIF), GRF and IGFs in mediating GH feedback was evaluated in hypothalamic-pituitary coperifusion. CLON-induced GH release in this system was associated with increased GRF and decreased SRIF release, and the pattern was reversed by hGH. The influence of hGH was mimicked by IGF-I (1.5 x 10(-8) M), except that the GH release was depressed below baseline levels, suggesting a direct effect of IGF-I on the pituitary. Furthermore, the inhibitory effect of hGH on the CLON-induced GH surge and hypothalamic releasing factors (increased SRIF and decreased GRF) was reversed by antisera to IGF-I (1:100), IGF-II (1:100), or both. To determine whether IGF-I is released from hypothalamus or pituitary in response to GH, tissues were tested separately in static incubation. As compared with basal levels, incubation of hypothalami with hGH increased IGF-I and SRIF and decreased GRF release. Because GH and IGF-I release remained unchanged when pituitaries were incubated alone with hGH, the site of IGF-I release and GH feedback is most likely at the hypothalamic level. To evaluate the role of IGFs on GH feedback in vivo, male rats were prepared with permanently implanted 3rd-ventricular and jugular cannulae. CLON was administered intravenously, and oGH, IGF-I (0.5 microgram/2 microliters), and IGF-I and -II antisera (1:100) were injected intraventricularly. In this as in in vitro studies, IGF-I mimicked the inhibitory feedback effect of GH on the CLON-induced GH surge, and IGF antisera blocked GH feedback. We propose that these studies suggest that endogenous hypothalamic IGF-I mediates the influence of GH in the feedback mechanism by increasing SRIF and depressing GRF release.
采用体内和体外(静态孵育和灌流)实验方法,研究胰岛素样生长因子(IGF)在生长激素(GH)反馈调节中的作用。注射α2 - 肾上腺素能激动剂可乐定(CLON;体外实验浓度为2×10⁻⁸ M,体内实验为静脉注射30微克/毫升/千克体重),以模拟触发GH释放的下丘脑机制,诱导GH分泌高峰。体外实验中,通过加入人GH(hGH;2×10⁻⁶ M)启动反馈调节;体内实验则通过脑室内注射羊GH(oGH)(20微克/2微升)启动反馈调节。体外实验结束时添加生长激素释放因子(GRF;1×10⁻⁸ M),以检测垂体的反应性。在体外下丘脑 - 垂体联合灌流实验中,评估生长抑素(SRIF)、GRF和IGF在介导GH反馈调节中的作用。在此系统中,CLON诱导的GH释放与GRF释放增加和SRIF释放减少相关,hGH可使此模式逆转。IGF - I(1.5×10⁻⁸ M)可模拟hGH的作用,但GH释放低于基线水平,提示IGF - I对垂体有直接作用。此外,针对IGF - I(1:100)、IGF - II(1:100)或两者的抗血清可逆转hGH对CLON诱导的GH分泌高峰及下丘脑释放因子(SRIF增加和GRF减少)的抑制作用。为确定IGF - I是否因GH作用而从下丘脑或垂体释放,分别对组织进行静态孵育实验。与基础水平相比,hGH孵育下丘脑可增加IGF - I和SRIF释放,并减少GRF释放。单独用hGH孵育垂体时,GH和IGF - I释放无变化,因此IGF - I释放及GH反馈调节的位点很可能在下丘脑水平。为评估IGF在体内GH反馈调节中的作用,给雄性大鼠永久性植入第三脑室和颈静脉插管。静脉注射CLON,并脑室内注射oGH、IGF - I(0.5微克/2微升)以及IGF - I和 - II抗血清(1:100)。与体外实验一样,在此实验中IGF - I模拟了GH对CLON诱导的GH分泌高峰的抑制性反馈作用,IGF抗血清可阻断GH反馈调节。我们认为,这些研究提示内源性下丘脑IGF - I通过增加SRIF释放和抑制GRF释放,在反馈调节机制中介导GH的作用。